

## **CERTIFICATE OF GDP COMPLIANCE**

We certify herewith

that the company **ebi-pharm ag, Lindachstrasse 8c, 3038 Kirchlindach,** Authorisation No. 511304-102618263 with its site **ebi-pharm ag, Lindachstrasse 8c, 3038 Kirchlindach, Switzerland**, Site No. 1000453 has been duly authorised to distribute medicinal products resp. API / intermediates according to the table below;

that the company is keeping the required level for Good Distribution Practices for Medicinal Products (GDP) according to the Swiss regulations in force. These regulations are in accordance with the requirements of the following documents:

- Guidelines of the European Commission on Good Distribution Practice of Medicinal Products for Human Use (2013/C 343/01)
- Commission Implementing Regulation (EU) 2021/1248 on Good Distribution Practice for Veterinary Medicinal Products
- Guidelines of the European Commission on Good Distribution Practice of active substances for medicinal products for human use (2015/C 95/01)
- Commission Implementing Regulation (EU) 2021/1280 on Good Distribution Practice for active substances for veterinary medicinal products

that the company is subject to official periodic inspections; the last regular inspection has been performed on **22.03.2022** (dd.mm.yyyy).

lo.	Operation	Scope*
6.2	IMPORT OF MEDICINAL PRODUCTS (WITHOUT LABILE BLOOD PRODUCTS)	7
he author	ised activities do not include the storage of medicinal products	16
5.2.2	Import of ready-to-use medicinal products, including market release	
5.2.2.1 5.2.2.2	Medicinal products (without immunological and blood products) Immunological medicinal products	Y =
5.2.6	Outsourcing of manufacture of medicinal products as contract giver	
5.4	WHOLESALE DISTRIBUTION OF MEDICINAL PRODUCTS (WITHOUT LABILE BLOOD PRODUCTS)	
The author	ised activities do not include the storage of medicinal products	1
5.4.1	Wholesale distribution of non- ready-to-use medicinal products	
S.4.1.1	Medicinal products (without immunological and blood products)	1-
S.4.2	Wholesale distribution of ready-to-use medicinal products, including market release	17
S.4.2.1	Medicinal products (without immunological and blood products)	

Schweizerisches Heilmittelinstitut Institut suisse des produits thérapeutiques Istituto svizzero per gli agenti terapeutici Swiss Agency for Therapeutic Products

I-303.AA.04-A05e / V3.0 / bja / gme / smi / 10.05.2022

Swissmedic | Hallerstrasse 7 | CH-3012 Bern | www.swissmedic.ch | Tel. +41 58 462 02 11 | Fax +41 58 462 02 12



No.	Operation		Scope*
S.4.6	Outsourcing of manufacture	of medicinal products as contract giver	1
S.5	EXPORT OF MEDICINAL PRO	DDUCTS (WITHOUT LABILE BLOOD PRODUCTS)	
The authorised	d activities do not include the stor	age of medicinal products	)
S.5.2	Export of ready-to-use medic	cinal products	
S.5.2.1	Medicinal products (without im	munological and blood products)	-
V Veterin	and veterinary medicinal products, w ary medicinal products only, without i investigational medicinal products		C
Berne, 24.0 No. GDP-CI	5.2022 (dd.mm.yyyy) H-1003231	Swissmedic, Swiss Agency for Therapeutic Products	
		E. Europey L	
		Eva Ehrensperger Murri	
			1

Schweizerisches Heilmittelinstitut Institut suisse des produits thérapeutiques Istituto svizzero per gli agenti terapeutici Swiss Agency for Therapeutic Products

Swissmedic | Hallerstrasse 7 | CH-3012 Bern | www.swissmedic.ch | Tel. +41 58 462 02 11 | Fax +41 58 462 02 12